Coronaviruses (CoVs) are highly diverse single-stranded RNA viruses owing to their susceptibility to numerous genomic mutations and recombination. Such viruses involve human and animal pathogens including the etiologic agents of acute respiratory tract illnesses: severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and the highly morbific SARS-CoV-2. Coronavirus disease 2019 (COVID-19), an emerging disease with a quick rise in infected cases and deaths, was recently identified causing a worldwide pandemic. COVID-19 disease outcomes were found to increase in elderly and patients with a compromised immune system. Evidences indicated that the main culprit behind COVID-19 deaths is the cytokine storm, which is illustrated by an uncontrolled over-production of soluble markers of inflammation. The regulation process of coronavirus pathogenesis through molecular mechanism comprise virus-host interactions linked to viral entry, replication and transcription, escape, and immune system control. Recognizing coronavirus infections and COVID-19 through epigenetics lens will lead to potential alteration in gene expression thus limiting coronavirus infections. Focusing on epigenetic therapies reaching clinical trials, clinically approved epigenetic-targeted agents, and combination therapy of antivirals and epigenetic drugs is currently considered an effective and valuable approach for viral replication and inflammatory overdrive control.

中文翻译：

---

表基因组网络的管理涉及冠状病毒感染和COVID-19。

冠状病毒（CoV）是高度多样的单链RNA病毒，由于它们易受众多基因组突变和重组的影响。此类病毒涉及人类和动物病原体，包括急性呼吸道疾病的病原体：严重急性呼吸综合征冠状病毒（SARS-CoV），中东呼吸综合征冠状病毒（MERS-CoV）和高度病态的SARS-CoV-2。最近发现冠状病毒病2019（COVID-19）是一种新兴疾病，感染病例和死亡人数迅速上升，目前已引起全球大流行。发现老年人和免疫系统受损的患者COVID-19疾病结局增加。有证据表明，导致COVID-19死亡的罪魁祸首是细胞因子风暴，这是由可溶的炎症标记物不受控制地过度生产所说明的。通过分子机制调节冠状病毒发病机理的过程包括与病毒进入，复制和转录，逃逸以及免疫系统控制有关的病毒-宿主相互作用。通过表观遗传学透镜识别冠状病毒感染和COVID-19将导致基因表达的潜在改变，从而限制了冠状病毒感染。专注于达到临床试验的表观遗传学疗法，临床认可的表观遗传学靶向药物以及抗病毒药和表观遗传学药物的联合治疗目前被认为是用于病毒复制和炎症超速控制的有效且有价值的方法。通过表观遗传学透镜识别冠状病毒感染和COVID-19将导致基因表达的潜在改变，从而限制了冠状病毒感染。专注于达到临床试验的表观遗传学疗法，临床认可的表观遗传学靶向药物以及抗病毒药和表观遗传学药物的联合治疗目前被认为是用于病毒复制和炎症超速控制的有效且有价值的方法。通过表观遗传学透镜识别冠状病毒感染和COVID-19将导致基因表达的潜在改变，从而限制了冠状病毒感染。专注于达到临床试验的表观遗传学疗法，临床认可的表观遗传学靶向药物以及抗病毒药和表观遗传学药物的联合治疗目前被认为是用于病毒复制和炎症超速控制的有效且有价值的方法。